1. Draw blood immediately before next scheduled dose.
2. For sustained-release formulations ONLY, draw blood a minimum of 12 hours after last dose.
3. Spin down within 2 hours of draw.
Rufinamide is a new antiepileptic drug approved by the Food and Drug Administration as add-on treatment for seizures associated with Lennox-Gastaut syndrome in children 4 years of age or older and for the treatment of focal seizures in adults and adolescents. Its mechanism of action is not completely understood, but it is believed to work by prolonging the inactive state of sodium channels, therefore limiting excessive firing of sodium-dependent action potentials. The commonly observed side effects are headache, dizziness, fatigue, somnolence, and nausea.